reports
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B in the attached file. Investor Relations Tobias Bjorklund Anders Enevoldsen Disa Tuominen Attachment
- ABGSC Renewable Energy Research
- Adrian Gilani
- Åsne Holsen
- Daniel Vårdal Haugland
- Haakon Amundsen
- John Olaisen
- Olof Cederholm
- Stian Wibstad
ORSTED ORSTED
HEX HEXAGON COMPOSITES ASA
NEL NEL ASA
SSO SCATEC ASA
EOLU B EOLUS VIND AB
FKRFT FJORDKRAFT HOLDING ASA
CADLR CADELER
VOLUE VOLUE AS
A2QKGG HEXAGON PURUS
ZAP ZAPTEC
VWS VESTAS WIND SYSTEMS
EWIND EDDA WIND ASA
TOM TOMRA SYSTEMS ASA
IWS-NO INTEGRATED WIND SOLUTIONS
OX2-SE OX2
- Niclas Gehin
Rana Gruber (Buy, TP: NOK90.00) - Volatile iron ore prices
Rana Gruber reported a mixed set of Q1 results, with accounting and hedging effects as well as volatile iron ore prices, which blurred much of the underlying operational result. We have lowered our 2024–2026e EPS by 1–3% on the results and our updated forecasts for the latest iron ore futures curve and FX changes. We continue to find a 2024e P/E of 7x on current spot rates attractive, while we await the benefits of the company’s upgrade to Fe 65% and potential further upgrades longer-term. We re...
- Marine Leleux
- Maureen Schuller
- Suvi Platerink Kosonen
Bank Brunch/PBB earnings, Sparebanken Vest 5yr covered, Green Raiffeis...
Deutsche Pfandbriefbank: loan quality pressures ease, preference for the shorter end of the preferred senior curve. Sparebanken Vest issues after Norwegian covered outperformance. Sub-benchmark green senior preferred from Raiffeisen Bank Hungary
- Marine Leleux
- Maureen Schuller
- Suvi Platerink Kosonen
Bank Brunch/PBB earnings, Sparebanken Vest 5yr covered, Green Raiffeis...
Deutsche Pfandbriefbank: loan quality pressures ease, preference for the shorter end of the preferred senior curve. Sparebanken Vest issues after Norwegian covered outperformance. Sub-benchmark green senior preferred from Raiffeisen Bank Hungary
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Håkon Astrup
SpareBank 1 Østlandet (Hold, TP: NOK140.00) - On HOLD after strong Q1
Fuelled by further NII expansion, the tax benefit of customer dividends, strong trading income and low loan losses, SPOL reported a Q1 ROE of 17.4% (>12% target), despite NOK26m of merger-related costs. We have made minor changes to our 2025–2026e EPS and reiterate our NOK140 target price. However, after the recent share price appreciation, we find more attractive risk/reward elsewhere in the sector. Thus, with the stock trading at a 2025e P/E of ~9.2x, we have downgraded to HOLD (BUY).
- Håkon Astrup
SpareBank1 Nord-Norge (Buy, TP: NOK115.00) - Loan-loss downtick
Helped by continued NII momentum and moderate loan losses, NONG reported a strong Q1 ROE of 17.8%, even with somewhat elevated cost inflation. Boosted by improved lending margins and decent lending growth, ‘real NII’ rose 1.7%, despite one less interest day and deposit margin pressure. While the CET1 ratio fell ~10bp QOQ, the bank has a solid ~120bp buffer to its 15.8% requirement, boding well for further generous dividend distributions. With the stock trading at a 2025e P/E of ~8.7x, we continu...
- Håkon Astrup
Sparebank 1 SMN (Buy, TP: NOK167.00) - Sustained NII momentum
Supported by further NII expansion, strong non-interest income and low loan losses, Q1 ROE was 16.0%, despite sustained cost pressure. Adjusted for the NOK59m positive one-off in Q4, ‘real NII’ rose another 7.3% QOQ, even with one fewer interest day. We have raised our 2025–2026e EPS by ~1–2%, driven by higher NII, and our target price to NOK167 (161). With the stock trading at a 2025e P/E of ~9.1x, we continue to find the valuation attractive and reiterate our BUY.
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- ABGSC Renewable Energy Research
- Adrian Gilani
- Åsne Holsen
- Daniel Vårdal Haugland
- Haakon Amundsen
- John Olaisen
- Olof Cederholm
- Stian Wibstad
ORSTED ORSTED
HEX HEXAGON COMPOSITES ASA
NEL NEL ASA
SSO SCATEC ASA
EOLU B EOLUS VIND AB
FKRFT FJORDKRAFT HOLDING ASA
CADLR CADELER
VOLUE VOLUE AS
A2QKGG HEXAGON PURUS
ZAP ZAPTEC
VWS VESTAS WIND SYSTEMS
EWIND EDDA WIND ASA
TOM TOMRA SYSTEMS ASA
IWS-NO INTEGRATED WIND SOLUTIONS
OX2-SE OX2
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- ABGSC Shipping & Transport Research
- Oliver Dunvold
- Petter Haugen
- Jesper Ingildsen
ALK-Abello (Buy, TP: DKK165.00) - European tablet growth shifts gear
Last night, ahead of time, ALK-Abello published its Q1 results and increased its FY top-line guidance on much stronger than expected European tablet sales growth of c28% (consensus c15%). At the same time, the company announced a cost-cutting programme in connection with its ongoing strategic review, which should help it reach its c25% EBIT margin target by 2025. We reiterate our BUY and have raised our target price to DKK165 (145).
Q1 update: Novonesis delivers 4% organic sales growth in line with exp...
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35%. COPENHAGEN, Denmark – May 3, 2024. In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator. The organic sales growth in the first quarter is driven by both Food & Health Biosolution...
Trading statement Q1 2024
Trading statement Q1 2024 Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It’s highly comforting to see our new organization’s focus on both short and long-term deliverables and developments.” Pro forma sales perfo...
Resolutions from the annual shareholders’ meeting 2024
Resolutions from the annual shareholders’ meeting 2024 Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.• Approval of the Remuneration Report fo...
- ABGSC Shipping & Transport Research
- Oliver Dunvold
- Petter Haugen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.